Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development fo...

Full description

Bibliographic Details
Main Authors: Monica Giovannini, Vanesa Gregorc, Carmen Belli, Elisa Roca, Chiara Lazzari, Maria Grazia Viganò, Anna Serafico, Eugenio Villa
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2009/849051
id doaj-876e545d0f0043d1845a1453c0c018b2
record_format Article
spelling doaj-876e545d0f0043d1845a1453c0c018b22020-11-24T23:07:08ZengHindawi LimitedJournal of Oncology1687-84501687-84692009-01-01200910.1155/2009/849051849051Clinical Significance of Skin Toxicity due to EGFR-Targeted TherapiesMonica Giovannini0Vanesa Gregorc1Carmen Belli2Elisa Roca3Chiara Lazzari4Maria Grazia Viganò5Anna Serafico6Eugenio Villa7Oncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyOncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, ItalyMany small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven.http://dx.doi.org/10.1155/2009/849051
collection DOAJ
language English
format Article
sources DOAJ
author Monica Giovannini
Vanesa Gregorc
Carmen Belli
Elisa Roca
Chiara Lazzari
Maria Grazia Viganò
Anna Serafico
Eugenio Villa
spellingShingle Monica Giovannini
Vanesa Gregorc
Carmen Belli
Elisa Roca
Chiara Lazzari
Maria Grazia Viganò
Anna Serafico
Eugenio Villa
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
Journal of Oncology
author_facet Monica Giovannini
Vanesa Gregorc
Carmen Belli
Elisa Roca
Chiara Lazzari
Maria Grazia Viganò
Anna Serafico
Eugenio Villa
author_sort Monica Giovannini
title Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
title_short Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
title_full Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
title_fullStr Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
title_full_unstemmed Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
title_sort clinical significance of skin toxicity due to egfr-targeted therapies
publisher Hindawi Limited
series Journal of Oncology
issn 1687-8450
1687-8469
publishDate 2009-01-01
description Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven.
url http://dx.doi.org/10.1155/2009/849051
work_keys_str_mv AT monicagiovannini clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT vanesagregorc clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT carmenbelli clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT elisaroca clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT chiaralazzari clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT mariagraziavigano clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT annaserafico clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
AT eugeniovilla clinicalsignificanceofskintoxicityduetoegfrtargetedtherapies
_version_ 1725619788087033856

Similar Items